Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics
This early marker distinguishes Alzheimer’s from controls and other neurodegenerative diseases more accurately than other biomarkers.
ALL NEWS
205 RESULTS
Sort By:
- Most Recent
- Most Commented
Could Common Vaccines Protect Against Alzheimer’s Disease?
In large population datasets, people who had been vaccinated against influenza or pneumonia appeared less likely to develop AD.
Micro Nudge? Positive Phase 2 Results for ALS Combination Drug
AMX0035, a mix of sodium phenylbutyrate and taurursodiol, slowed functional decline over six months by about as much as the approved ALS drug edaravone.
Introducing the Coarse-Grained Plaque—A New Type of Amyloid
Comprising mostly Aβ40, these large plaques are shot through with strange tubular structures and BBB markers. They are common in early onset AD.
NIA Weighs in on Neurodegenerative Disease Transmissibility
Expert panel concludes there’s little risk based on current evidence.
Does Alzheimer’s Start in the Heart of the Cholinergic System?
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.
In Mice, Activating TREM2 Tempers Plaque Toxicity, not Load
Alector’s AL002c antibody mobilizes microglia, reduces neuronal dystrophy, and restores normal behavior—all in mice. The clinical version is in Phase 1.
New Funding for Tauopathies
A $400,000 prize is to be awarded as part of the new Rainwater program, and $63 million of NIH money will support a research consortium on frontotemporal dementias.
Human Microglia Eat Synapses, More So in Alzheimer’s
Evidence from postmortem human brains and cultured human microglia suggests the immune cells make a meal out of synapses, especially near plaques.
Dipeptide Repeat Proteins Don’t Directly Block Nuclear Transport
New data suggest that while peptides translated from an expansion in the C9ORF72 gene are toxic, they don’t directly interfere with nucleocytoplasmic transport.
Minocycline Does Not Work in Mild Alzheimer’s Disease
Based on preclinical data, researchers gave this antibiotic a shot in a two-year clinical trial. It did nothing to slow cognitive decline.
Society for Neuroscience Annual Meeting 2019
Not Just Blood Pressure—Dietary Salt Linked to Tau Phosphorylation Time to Try Again: Gene-Based Therapy for Neurodegeneration Gene Therapies Enter Trials for Many Brain Pathologies—What about AD? Organized around 10 major themes, this year’s annual meeti
Clinical Trials on Alzheimer's Disease 2019
Exposure, Exposure, Exposure? At CTAD, Aducanumab Scientists Make a Case Fluid AD Biomarkers Link P-Tau to Synapses, Inflammation Blood Tests of Phospho-Tau, Aβ42, Track With Brain Amyloid Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe. Picking T
Gosuranemab, Biogen’s Anti-Tau Immunotherapy, Does Not Fly for PSP
In PASSPORT study, the antibody failed to slow progressive supranuclear palsy. Alzheimer’s trial to continue.
Fluid AD Biomarkers Link P-Tau to Synapses, Inflammation
An expanded set of CSF biomarkers exposed tight connections between p-tau, synaptic dysfunction, and neuroinflammation in people with brain amyloid.
Current Filters
- Date Range : Oct 2019 to Oct 2020 x